Valvular Aortic valve

Mitral valve

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently...

Dr. Carlos Fava - 20 June, 2025

Learn More

Chronic Ischemic cardiopathy

IVUS Assessment in Patients at High Risk of Coronary Occlusion After TAVI: Results from the ICARO Study

Courtesy of Dr. Juan Manuel Pérez. Acute coronary obstruction (ACO) is a rare but potentially fatal complication following...

Dr. Juan Manuel Pérez - 4 June, 2025

Learn More

Structural heart disease

Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy....

Dr. Carlos Fava - 4 June, 2025

Learn More

Other

Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes

Tricuspid regurgitation (TR) has been associated with increased mortality and functional deterioration. Even though the current guidelines...

Dr. Andrés Rodríguez - 2 June, 2025

Learn More

Mitral valve

EuroPCR 2025 | TRI-SCORE for Predicting Mortality After Tricuspid Valve TEER: The EURO TR Registry

Researchers analyzed a total of 1062 patients who underwent transcatheter edge-to-edge repair (TEER) for tricuspid regurgitation (TR). Risk...

Dr. Carlos Fava - 26 May, 2025

Learn More

Mitral valve

EuroPCR 2025 | One-Year Results of Pivotal Study in China with Dragonfly for Functional Mitral Regurgitation

Researchers assessed a total of 120 patients with symptomatic severe functional mitral regurgitation despite receiving optimal guideline-directed medical...

Dr. Carlos Fava - 26 May, 2025

Learn More

Structural heart disease

EuroPCR 2025 | Individual Patient Data Meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI

Stroke remains a significant complication associated with the various transcatheter aortic valve implantation (TAVI) devices currently in...

Dr. Omar Tupayachi - 22 May, 2025

Learn More

Chronic Ischemic cardiopathy

EuroPCR 2025 | Angiography- vs. Physiology-Guided PCI in TAVI Candidates (FAITAVI)

Coronary artery disease is present in 50 to 70% of TAVI candidates and over 90% of these...

Dr. Omar Tupayachi - 22 May, 2025

Learn More

Edge-to-Edge Treatment in Cardiogenic Shock

IVUS Assessment in Patients at High Risk of Coronary Occlusion After TAVI: Results from the ICARO Study

Decompensated Aortic Stenosis: Time to TAVR Matters

Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes

EuroPCR 2025 | TRI-SCORE for Predicting Mortality After Tricuspid Valve TEER: The EURO TR Registry

EuroPCR 2025 | One-Year Results of Pivotal Study in China with Dragonfly for Functional Mitral Regurgitation

EuroPCR 2025 | Individual Patient Data Meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI

EuroPCR 2025 | Angiography- vs. Physiology-Guided PCI in TAVI Candidates (FAITAVI)

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Access